soul trial oral semaglutide trial: 14 mg demonstrated superior reduction in risk of CV events Oral GLP-1 Receptor Agonist Reduces

Which GLP-1 medications commonly cause diarrhea

not available to Medicare or Medicaid)

FDA Submission Timeline Based on the TRIUMPH-4 success and expected 2026 readouts, analysts predict: Late 2026: Completion of core TRIUMPH trials Q4 2026 or Q1 2027: New Drug Application (NDA) submission to FDA Mid to Late 2027: Potential FDA approval Early 2028: Commercial launch Eli Lilly has not officially confirmed these timelines, but the company has indicated it will submit for regulatory approval once sufficient Phase 3 data is available

Its inclusion in QUAD is a clinician-directed compounding decision, not an FDA-approved use for this indication

Semalix 14 mg Tablet should be taken once daily, first thing in the morning, on an empty stomach